Condition
Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Total Trials
2
Recruiting
0
Active
1
Completed
0
Key Insights
Highlights
Treatment Research
4 treatments under study, led by Nonconforming Pzcel Surgical Application To Rdeb Wounds
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
50%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
Phase 1/2 (1)
Phase 4 (1)
Trial Status
Not Yet Recruiting1
Active Not Recruiting1
Clinical Trials (2)
Showing 2 of 2 trials
NCT07717736Phase 4Not Yet Recruiting
Phase 4 Master Protocol for Patients Prescribed Prademagene Zamikeracel for the Treatment of Wounds
NCT04186650Phase 1/2Active Not Recruiting
Ex Vivo Gene Therapy Clinical Trial for RDEB Using Genetically Corrected Autologous Skin Equivalent Grafts
Showing all 2 trials
Research Network
Common Treatments
- Nonconforming Pzcel Surgical Application To Rdeb Wounds1
- Pzcel Surgical Application To Deb Wounds1
- Additional Biopsies1
- Col7a1sin Retroviral Vector Engineered Autologous Tissueengineered Skin1
Active Sponsors
- Institut National de la Santé Et de la Recherche Médicale, France1
- Abeona Therapeutics, Inc1
Related Conditions
- Epidermolysis Bullosa Eb1
- Dystrophic Epidermolysis Bullosa Deb1
- Epidermolysis Bullosa Dystrophica Recessive1